close

Vor Bio to Participate in the JMP Securities Hematology and Oncology Summit

CAMBRIDGE, Mass., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in a fireside chat and host virtual 1x1 investor meetings at the JMP Securities Hematology and Oncology Summit.

JMP Securities Hematology and Oncology Summit
Fireside Chat: Tuesday, December 5, 2023 at 1:30 pm ET
Location: Virtual

About Vor Bio
Vor Bio is a clinical-stage cell and genome engineering company that aims to change the standard of care for patients with blood cancers by engineering hematopoietic stem cells to enable targeted therapies post-transplant. For more information, visit: www.vorbio.com.

Contact:

Media & Investors
Sarah Spencer
+1 857-242-6076
sspencer@vorbio.com


Primary Logo

More News

View More

Recent Quotes

View More
Symbol Price Change (%)
AMZN  222.49
-0.05 (-0.02%)
AAPL  274.39
+0.28 (0.10%)
AMD  208.35
+0.77 (0.37%)
BAC  55.05
-0.27 (-0.50%)
GOOG  306.60
-2.72 (-0.88%)
META  658.36
+10.85 (1.68%)
MSFT  476.46
+1.64 (0.35%)
NVDA  176.95
+0.66 (0.37%)
ORCL  188.99
+4.07 (2.20%)
TSLA  486.14
+10.83 (2.28%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Starting at $3.75/week.

Subscribe Today